These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38812772)

  • 1. Diagnostic value of combined detection of plasma cfDNA concentration and integrity in NSCLC.
    Ren S; Yu C; Huang Q
    Lung Cancer Manag; 2024; 13(1):LMT64. PubMed ID: 38812772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinations of plasma cfDNA concentration, integrity and tumor markers are promising biomarkers for early diagnosis of non-small cell lung cancer.
    Ren S; Zeng G; Yi Y; Liu L; Tu H; Chai T; Hu L
    Heliyon; 2023 Oct; 9(10):e20851. PubMed ID: 37860559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.
    Szpechcinski A; Rudzinski P; Kupis W; Langfort R; Orlowski T; Chorostowska-Wynimko J
    Cancer Lett; 2016 May; 374(2):202-7. PubMed ID: 26854716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
    Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
    Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease.
    Szpechcinski A; Chorostowska-Wynimko J; Struniawski R; Kupis W; Rudzinski P; Langfort R; Puscinska E; Bielen P; Sliwinski P; Orlowski T
    Br J Cancer; 2015 Jul; 113(3):476-83. PubMed ID: 26125447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice.
    González de Aledo-Castillo JM; Arcocha A; Victoria I; Martinez-Puchol AI; Sánchez C; Jares P; Rodríguez GF; Viñolas N; Reyes R; Reguart N; Puig-Butillé JA
    J Thorac Dis; 2021 Mar; 13(3):1658-1670. PubMed ID: 33841957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
    Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
    Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A quantitative analysis of the potential biomarkers of non-small cell lung cancer by circulating cell-free DNA.
    Wei L; Wu W; Han L; Yu W; Du Y
    Oncol Lett; 2018 Oct; 16(4):4353-4360. PubMed ID: 30250538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
    Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
    Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study.
    Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M
    Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in laryngeal squamous cell carcinoma.
    Huang Q; Ji M; Li F; Li Y; Zhou X; Hsueh CY; Zhou L
    Mol Cell Probes; 2023 Feb; 67():101895. PubMed ID: 36682577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring early dynamic changes of plasma cell-free DNA and pretreatment pre-albumin to predict chemotherapy effectiveness and survival outcomes in advanced non-small cell lung cancer.
    Chen J; Shao J; Zhang X; Wei S; Cai H; Wang G
    Ann Transl Med; 2022 Mar; 10(5):253. PubMed ID: 35402598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine cell-free DNA as a promising biomarker for early detection of non-small cell lung cancer.
    Ren S; Ren XD; Guo LF; Qu XM; Shang MY; Dai XT; Huang Q
    J Clin Lab Anal; 2020 Aug; 34(8):e23321. PubMed ID: 32281142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer.
    Peng WW; Liu Y; Sha HH; Wen SD; Fang Y; Zhou GR
    BMC Pulm Med; 2023 Sep; 23(1):348. PubMed ID: 37710221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
    Mastoraki S; Balgkouranidou I; Tsaroucha E; Klinakis A; Georgoulias V; Lianidou E
    Mol Oncol; 2021 Sep; 15(9):2412-2422. PubMed ID: 33159839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer.
    Balgkouranidou I; Chimonidou M; Milaki G; Tsarouxa EG; Kakolyris S; Welch DR; Georgoulias V; Lianidou ES
    Br J Cancer; 2014 Apr; 110(8):2054-62. PubMed ID: 24642624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The analysis of cell-free DNA concentrations and integrity in serum of initial and treated of lymphoma patients.
    Wu J; Tang W; Huang L; Hou N; Wu J; Cheng X; Ma D; Qian P; Shen Q; Guo W; Peng W; Liu Y; Jiang C; Feng J
    Clin Biochem; 2019 Jan; 63():59-65. PubMed ID: 30292543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis.
    Madhavan D; Wallwiener M; Bents K; Zucknick M; Nees J; Schott S; Cuk K; Riethdorf S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Surowy H; Burwinkel B
    Breast Cancer Res Treat; 2014 Jul; 146(1):163-74. PubMed ID: 24838941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and meta-analysis of circulating cell-free DNA as a diagnostic biomarker for non-small cell lung cancer.
    He X; Chi Y; Peng J; Hu W; Ding C; Li B
    J Thorac Dis; 2022 Jun; 14(6):2103-2111. PubMed ID: 35813759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of plasma cfDNA concentration and integrity in breast cancer patients.
    Miao Y; Fan Y; Zhang L; Ma T; Li R
    Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):64-72. PubMed ID: 31472049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.